Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for prostate cancer.

Stephen Frankel1, George Davey Smith, Jenny Donovan

  • 1Department of Social Medicine, University of Bristol, Canynge Hall, BS8 2PR, Bristol, UK. zetkin@bristol.ac.uk <zetkin@bristol.ac.uk>

Lancet (London, England)
|April 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Online peer support for Young Onset Dementia is a promising resource, but not a panacea: a commentary from the INTERDEM Young Onset Dementia taskforce.

Frontiers in dementia·2025
Same author

Biases in an artificial intelligence image-generator's depictions of healthy aging and Alzheimer's.

Journal of the American Medical Informatics Association : JAMIA·2025
Same author

Recommendations for the development and use of technology to support people living with dementia and caregivers: A Delphi study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Digital assistive technologies for community-dwelling people with dementia: A systematic review of systematic reviews by the INTERDEM AI & assistive technology taskforce.

Digital health·2025
Same author

What are the unmet needs in people affected by dementia? A scoping review of reviews.

Aging & mental health·2025
Same author

Effective for Whom? A Review of Psychological and Social Intervention Recommendations in European Dementia Care Guidelines Through the Lenses of Social Health and Intersectionality.

Behavioral sciences (Basel, Switzerland)·2025

Prostate cancer screening offers limited benefits and clear harms, especially in low-risk groups. Its justification is currently limited to research settings for effectiveness assessment and identifying potential beneficiaries.

Area of Science:

  • Urology
  • Oncology
  • Public Health

Background:

  • Prostate cancer is a significant disease with limited primary prevention options.
  • The natural history of prostate cancer complicates screening justification, as men often die with it rather than from it.
  • Current screening tests may not reliably identify aggressive cancers, and treatment benefits for screen-detected localized cancers are uncertain.

Purpose of the Study:

  • To evaluate the epidemiological justification for prostate cancer screening.
  • To assess the balance of benefits and harms associated with prostate cancer screening programs.
  • To determine the conditions under which prostate cancer screening might be justified.

Main Methods:

  • Review of epidemiological data and natural history of prostate cancer.

Related Experiment Videos

  • Analysis of evidence regarding the effectiveness of screening tests and treatments for localized cancers.
  • Examination of observational data on population screening programs and their impact on mortality.
  • Consideration of risk stratification strategies to potentially improve the benefit-harm balance.

    • Main Results:

    • Evidence for the benefits of prostate cancer screening is limited, while harms are clearly established.
    • Observational data on screening programs show mixed results, with no definitive link between screening intensity and reduced mortality.
    • Screening is not justifiable in low-risk populations.
    • Risk stratification may improve the benefit-harm ratio.

    Conclusions:

    • Prostate cancer screening is not currently justified outside of research settings.
    • Research programs are needed to assess screening effectiveness and identify subgroups who may benefit.
    • The decision to screen should consider the limited benefits, clear harms, and the potential for risk stratification.